Itacitinib
Phase 3Small molecule
IncyteItacitinib is an experimental drug being studied to treat blood cancers and certain immune system disorders by blocking proteins that help cancer cells or abnormal immune cells grow.[1] Itacitinib is currently being investigated across 25 indications[3], with its most advanced program in Phase 3.[1]
Itacitinib is one of 514 small molecule programs targeting Bronchiolitis Obliterans. It is currently in Phase 3.
25
Indications
47
Total Trials
7
Active Trials
513
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 24 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Itacitinib
IncytePhase 3
Blenoxane
SSequus Pharmaceuticals
Preclinical
Velban
EEastern Cooperative Oncology Group
Preclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Tafasitamab
IncytePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
PEG-Intron
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Myelofibrosis4 trials
Acute Graft Versus Host Disease4 trials
Show 1 more trial
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
Terminated·—·Phase 1·NCT04070781·1 enrolled
Graft Versus Host Disease4 trials
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
Active, not recruiting·—·Phase 2·NCT05364762·20 enrolled
Show 1 more trial
Advanced Solid Tumors3 trials
Non-Small Cell Lung Cancer3 trials
27 more indications
Bronchiolitis Obliterans2 trials
Chronic Graft Versus Host Disease2 trials
Corticosteroids1 trial
Immunotherapy1 trial
Rheumatoid Arthritis1 trial
Function1 trial
Transplantation1 trial
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT05823571·32 enrolled
Lymphoma1 trial
Ulcerative Colitis1 trial
Psoriasis1 trial
Cytokine Release Syndrome1 trial
First-line Treatment1 trial
Immune Checkpoint Inhibitors1 trial
Refractory Metastatic1 trial
Small Cell Lung Cancer1 trial
Prophylaxis1 trial
T-Cell Prolymphocytic Leukemia1 trial
Diffuse Large B-Cell Lymphoma1 trial
Overlap Syndrome1 trial
B-cell Malignancies1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Itacitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]